Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.57 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065424 | 0.85 | KDM4E (0.55) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL7234834 | 0.84 | ESR2 (0.77) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL7237389 | 0.84 | ESR2 (0.77) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL21666743 | 0.82 | MAOA (0.67) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL7227675 | 0.80 | MAOA (0.78) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL7236943 | 0.80 | MAOA (0.78) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| Xanthone SCHEMBL41161 | 0.80 | MAOA (1.00) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| Xanthone SCHEMBL29398266 | 0.80 | MAOA (1.00) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| SCHEMBL4696277 | 0.80 | MAOA (0.90) | MAOAKDM4EALDH1A1CYP3A4GLA | |
| Xanthone SCHEMBL29358061 | 0.80 | MAOA (1.00) | MAOAKDM4EALDH1A1CYP3A4GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023280767-A1 | SANGENNON FOR ANTIVIRAL TREATMENT | Universität Wien (AT) | 2023-01-12 | — | — | WO | disclosed |
| US-11332474-B2 | Compound and organic light-emission device | LG DISPLAY CO., LTD. (KR) | 2022-05-17 | — | — | US | disclosed |
| US-20200048273-A1 | COMPOUND AND ORGANIC LIGHT-EMISSION DEVICE | LG DISPLAY CO., LTD. (KR) | 2020-02-13 | — | — | US | disclosed |
| US-20160214982-A1 | Radiosynthesis of Tau Radiopharmaceuticals | THE GENERAL HOSPITAL CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | disclosed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214982-A1 | Radiosynthesis of Tau Radiopharmaceuticals | MAPT, HTR7, TTBK2 | MAOA 227/4885KDM4E 3059/4885ALDH1A1 1907/4885 |
| US-20200048273-A1 | COMPOUND AND ORGANIC LIGHT-EMISSION DEVICE | TRPC4, TRPA1, TRPC1 | MAOA 1058/4885KDM4E 1601/4885ALDH1A1 721/4885 |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | ESR1, GPER1, ESR2 | MAOA 716/4885KDM4E 806/4885ALDH1A1 758/4885 |
| US-11332474-B2 | Compound and organic light-emission device | TRPC4, TRPA1, TRPC1 | MAOA 1058/4885KDM4E 1601/4885ALDH1A1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.